Trifecta Research Study

This interventional trial (n=40) will evaluate the safety and effectiveness of hormone replacement therapy (HRT), magnetic resonance therapy (MeRT), ibogaine, and 5-MeO-DMT in treating post-traumatic stress disorder (PTSD) and cognitive difficulties in Special Operations Forces veterans with a history of combat deployment and traumatic brain injury (TBI).

Sponsored by the Special Operations Care Fund (SOC-F) and conducted by the Johns Hopkins Center for Psychedelic and Consciousness Research, this study will assign participants to two different sequences of interventions to assess their impact on PTSD symptoms and cognitive function.

Participants will undergo treatment with HRT, followed by either MeRT or ibogaine and 5-MeO-DMT, with self-reported surveys, cognitive assessments, and informant reports tracking changes. The primary outcome measures include PTSD symptom reduction, cognitive function improvement, and emotional memory processing. The study also aims to determine whether the order of treatments influences effectiveness. Findings from this trial may help guide future clinical trials and improve treatment options for veterans with severe, treatment-resistant PTSD and cognitive impairment.

Topic Traumatic Brain Injury PTSD Neuroscience
Compound 5-MeO-DMT Ibogaine
Country United States of America
Visit trial
Status Not yet recruiting
Results Published No
Start date 01 March 2025
End date 01 March 2027
Phase Phase II
Design Open
Type Interventional
Generation First
Participants 40
Sex All
Age 18- 99
Therapy Yes

Trial Details

The Special Operations Care-Fund (SOC-F) will sponsor the application of four treatments - hormone replacement, magnetic resonance brain stimulation, ibogaine, and 5-Meo-DMT - to Special Operations Forces veterans with a history of combat deployments, traumatic brain injury, and problems with mental health and cognitive functioning. An observational study will be conducted in parallel by the Johns Hopkins Center for Psychedelic and Consciousness Research to determine the effectiveness and safety of each treatment, primarily through measuring post-treatment changes in PTSD symptoms and cognitive functioning.

Trial Number NCT06810765

Sponsors & Collaborators

Johns Hopkins University
Johns Hopkins University (Medicine) is host to the Center for Psychedelic and Consciousness Research, which is one of the leading research institutes into psychedelics. The center is led by Roland Griffiths and Matthew Johnson.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.